VECTORITE BIOMEDICAL INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15 TWD | -1.32% |
|
-2.28% | -29.74% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 42.91M 1.32M | Sales 2023 | 55.85M 1.72M | Capitalization | 935M 28.83M |
|---|---|---|---|---|---|
| Net income 2022 | -26M -802K | Net income 2023 | -6M -185K | EV / Sales 2022 | 9.5 x |
| Net cash position 2022 | 214M 6.59M | Net cash position 2023 | 204M 6.28M | EV / Sales 2023 | 13.1 x |
| P/E ratio 2022 |
-23.3
x | P/E ratio 2023 |
-142
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.37% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.32% | ||
| 1 week | -2.28% | ||
| Current month | -2.28% | ||
| 1 month | -5.06% | ||
| 3 months | -0.66% | ||
| 6 months | +5.71% | ||
| Current year | -29.74% |
1 week
14.95
15.55
1 month
14.4016.50
Current year
14.4021.35
1 year
14.4027.20
3 years
14.4027.20
5 years
8.9334.17
10 years
8.93142.26
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Chang Ou
CEO | Chief Executive Officer | - | 16-12-31 |
Hui Ching Yu
DFI | Director of Finance/CFO | - | 20-03-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shih Hsing Tsai
BRD | Director/Board Member | - | 05-02-28 |
So Chu Chang
CHM | Chairman | - | 19-06-19 |
Pai Jung Lai
BRD | Director/Board Member | - | 19-06-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 15 | -1.32% | 43,671 |
| 24-05-07 | 15.2 | -0.33% | 110,241 |
| 24-05-06 | 15.25 | +0.99% | 86,325 |
| 24-05-03 | 15.1 | 0.00% | 50,828 |
| 24-05-02 | 15.1 | -1.63% | 58,957 |
End-of-day quote Taipei Exchange, May 07, 2024
More quotes
Vectorite Biomedical Inc is a Taiwan-based company mainly engaged in providing cell product commissioned production services and cell preparations. Products include dendritic cell (DC) vaccines, and natural killer (NK) cell preparations for cancer treatment. The Company also provides immune cell collection, processing and storage services, cell preparation safety testing services, anti-cancer immunity testing services, original design manufacturer (ODM)/ contract development and manufacturing organization (CDMO) services, related medical consulting services, and laboratory quality management services. Products are mainly sold domestically.
| 1st Jan change | Capi. | |
|---|---|---|
| -29.74% | 20.26M | |
| +2.93% | 108B | |
| +7.02% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- 4170 Stock